Xtant Medical (NYSEAMERICAN:XTNT) Issues Earnings Results

Xtant Medical (NYSEAMERICAN:XTNTGet Free Report) announced its quarterly earnings results on Wednesday. The medical device company reported ($0.03) EPS for the quarter, reports. Xtant Medical had a negative net margin of 1.64% and a negative return on equity of 3.60%. The company had revenue of $27.87 million during the quarter.

Xtant Medical Price Performance

XTNT stock opened at $0.72 on Friday. Xtant Medical has a 1-year low of $0.60 and a 1-year high of $1.45. The company has a current ratio of 2.34, a quick ratio of 1.22 and a debt-to-equity ratio of 0.35.

Wall Street Analysts Forecast Growth

Separately, BTIG Research upped their target price on shares of Xtant Medical from $2.00 to $3.00 and gave the company a “buy” rating in a research note on Thursday.

Read Our Latest Stock Analysis on Xtant Medical

Institutional Trading of Xtant Medical

A number of large investors have recently bought and sold shares of XTNT. Juniper Investment Company LLC acquired a new position in shares of Xtant Medical during the first quarter worth about $408,000. Vanguard Group Inc. boosted its holdings in shares of Xtant Medical by 3.2% during the first quarter. Vanguard Group Inc. now owns 1,548,312 shares of the medical device company’s stock worth $1,812,000 after acquiring an additional 48,319 shares during the period. AWM Investment Company Inc. bought a new stake in Xtant Medical in the 3rd quarter valued at $516,000. Sterling Investment Advisors Ltd. acquired a new position in Xtant Medical in the 3rd quarter valued at $38,000. Finally, AMH Equity Ltd bought a new position in Xtant Medical during the 3rd quarter worth $653,000. 69.33% of the stock is owned by institutional investors.

About Xtant Medical

(Get Free Report)

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.

See Also

Earnings History for Xtant Medical (NYSEAMERICAN:XTNT)

Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.